/clinical/,/clinical/tools-resources/,/clinical/tools-resources/lab-test-directory/,/clinical/tools-resources/lab-test-directory/histocompatibility/,

/clinical/tools-resources/lab-test-directory/histocompatibility/name-68895-en.labtest

Mar 16, 2016

page

100

UWHC,UWMF,

Clinical Hub,Tools & Resources,UWHC Lab Test Directory,Histocompatibility

HLA DR Locus

HLA DR Locus (HCDRB1S (if Pre-Tx) , HCDRB1B (if Post-Tx)) Histocompatibility Lab Test

Name: HLA DR Locus

Test Name: HLA DR Locus

Health Link Test Code: HCDRB1S (if Pre-Tx) , HCDRB1B (if Post-Tx)

LIS Test Code: LRDRBS (if Pre-Tx) , LRDRBB (if Post-Tx)

CPT Code(s): 81376

Test Component:

Low-to-mid level resolution HLA Class II DRB1 loci typing. Identifies DR1-18, some at the allele level and some at the group level.

Methodology: Reverse SSO detected by Luminex xMAP (Multi-Analyte Profiling)

Clinical Information:

HLA-DRB1 loci low-to-mid level resolution typing typically used to match donor and recipients for organ transplantation. Also may be used to identify the presence of HLA-DRB alleles associated with some diseases (specify allele or disease under investigation in the request to assure proper interpretation).

Days Performed: Mon-Fri.

In-Lab Turnaround Time: 1 week.

Stat In-Lab Turnaround Time: Not available stat.

Patient Preparation:

No transfusions (RBC, WBC, Platelets) within 24 hours prior to collection.

Specimen: Blood

Collection Container: Lavender top

Also Acceptable: Yellow top(with ACD-A/B anticoagulant)

Collection Volume: 4 mL

Pediatric Collection Volume: 1 mL

Stability Ambient:

7 days

Stability Refridgerated:

3 weeks

Stability Frozen:

Not acceptable

Testing Volume: 4 mL

Pediatric Testing Volume: 1 mL

Specimen Transport:

Transport whole blood specimen at room temperature or refrigerated to UWHC Hospital Laboratory.

Interpretation:

A written interpretive report will be provided.

Additional Information:

If sufficient DNA can be extracted from specimen, the excess DNA will be held by the laboratory for approximately six months for additional high-resolution HLA typing.

 

This test was developed and its performance characteristics determined by this laboratory.  It has not been cleared or approved by the US Food and Drug Administration.  The FDA has determined that such clearance or approval is not necessary.  This test is used for clinical purposes.  It should not be regarded as investigational or for research.  This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.